| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 619* | 2019 |
| New gene functions in megakaryopoiesis and platelet formation C Gieger, A Radhakrishnan, A Cvejic, W Tang, E Porcu, G Pistis, ... Nature 480 (7376), 201-208, 2011 | 478 | 2011 |
| Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide MA Dimopoulos, A Anagnostopoulos, MC Kyrtsonis, K Zervas, C Tsatalas, ... Journal of Clinical Oncology 25 (22), 3344-3349, 2007 | 345 | 2007 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 257 | 2017 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 248 | 2021 |
| Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G … A Mouzaki, M Theodoropoulou, I Gianakopoulos, V Vlaha, MC Kyrtsonis, ... Blood, The Journal of the American Society of Hematology 100 (5), 1774-1779, 2002 | 214 | 2002 |
| Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European … MA Dimopoulos, R García-Sanz, M Gavriatopoulou, P Morel, ... Blood, The Journal of the American Society of Hematology 122 (19), 3276-3282, 2013 | 202 | 2013 |
| Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma MC Kyrtsonis, TP Vassilakopoulos, N Kafasi, S Sachanas, T Tzenou, ... British journal of haematology 137 (3), 240-243, 2007 | 202 | 2007 |
| Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents MA Dimopoulos, S Delimpasi, E Katodritou, A Vassou, MC Kyrtsonis, ... Annals of oncology 25 (1), 195-200, 2014 | 175 | 2014 |
| Bone resorption is increased in young adults with thalassaemia major E Voskaridou, MC Kyrtsonis, E Terpos, M Skordili, I Theodoropoulos, ... British journal of haematology 112 (1), 36-41, 2001 | 148 | 2001 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care TP Vassilakopoulos, GA Pangalis, A Katsigiannis, SG Papageorgiou, ... The oncologist 17 (2), 239-249, 2012 | 135 | 2012 |
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ... Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015 | 129 | 2015 |
| Rituximab monotherapy is highly effective in splenic marginal zone lymphoma C Kalpadakis, GA Pangalis, MN Dimopoulou, TP Vassilakopoulos, ... Hematological oncology 25 (3), 127-131, 2007 | 119 | 2007 |
| Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center O Nicolatou-Galitis, E Papadopoulou, T Sarri, P Boziari, A Karayianni, ... Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and …, 2011 | 112 | 2011 |
| Soluble interleukin‐6 receptor (sIL‐6R), a new prognostic factor in multiple myeloma MC KYRTSONIS, G Dedoussis, C Zervas, V Perifanis, C Baxevanis, ... British journal of haematology 93 (2), 398-400, 1996 | 105 | 1996 |
| Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy C Kalpadakis, GA Pangalis, MK Angelopoulou, S Sachanas, ... The Oncologist 18 (2), 190-197, 2013 | 100 | 2013 |
| Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first … MA Dimopoulos, A Pouli, K Zervas, V Grigoraki, A Symeonidis, ... Annals of oncology 14 (7), 1039-1044, 2003 | 100 | 2003 |
| Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients: Experience from a single hematology unit MC Kyrtsonis, T Vassilakopoulos, M Angelopoulou, M Siakantaris, ... Annals of hematology 80, 722-727, 2001 | 99 | 2001 |
| Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma E Kastritis, F Zagouri, A Symeonidis, M Roussou, A Sioni, A Pouli, ... Leukemia 28 (10), 2075-2079, 2014 | 80 | 2014 |
| Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 … E Katodritou, E Terpos, AS Symeonidis, A Pouli, C Kelaidi, MC Kyrtsonis, ... American journal of hematology 89 (8), 803-808, 2014 | 80 | 2014 |
